Cargando…

Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors

Inhibitors of fibroblast growth factor receptor (FGFR) represent an outstanding treatment approach for selected patients with urothelial cancer (UC). These agents are changing the clinical approach to a subgroup of UC, the luminal-papillary subtype, characterized by FGFR mutations, fusions, or ampli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Casadei, Chiara, Dizman, Nazli, Schepisi, Giuseppe, Cursano, Maria Concetta, Basso, Umberto, Santini, Daniele, Pal, Sumanta K., De Giorgi, Ugo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6878604/ https://www.ncbi.nlm.nih.gov/pubmed/31803255 http://dx.doi.org/10.1177/1758835919890285

Ejemplares similares

CAR-T cell therapy: a potential new strategy against prostate cancer
por: Schepisi, Giuseppe, et al.
Publicado: (2019)

Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell Tumors
por: Schepisi, Giuseppe, et al.
Publicado: (2023)

Prognostic Role of Systemic Inflammatory Indexes in Germ Cell Tumors Treated With High-Dose Chemotherapy
por: Cursano, Maria Concetta, et al.
Publicado: (2020)

Inflammatory Biomarkers as Predictors of Response to Immunotherapy in Urological Tumors
por: Schepisi, Giuseppe, et al.
Publicado: (2019)

Therapeutic Sequencing in Metastatic Renal Cell Carcinoma
por: Maia, Manuel Caitano, et al.
Publicado: (2017)

Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors
por: Schepisi, Giuseppe, et al.
Publicado: (2020)

Inflammatory Biomarkers for Outcome Prediction in Patients With Metastatic Testicular Cancer
por: Bleve, Sara, et al.
Publicado: (2022)

Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy
por: Conteduca, Vincenza, et al.
Publicado: (2020)

Impact of Somatic DNA Repair Mutations on the Clinical Outcomes of Bone Metastases from Castration-Resistant Prostate Cancer
por: Cursano, Maria Concetta, et al.
Publicado: (2023)

Metastasis in renal cell carcinoma: Biology and implications for therapy
por: Gong, Jun, et al.
Publicado: (2016)

Concomitant Radioembolization and Immune Checkpoint Inhibition in Metastatic Renal Cell Carcinoma
por: Adashek, Jacob J., et al.
Publicado: (2018)

Caregiver Emotional Burden in Testicular Cancer Patients: From Patient to Caregiver Support
por: De Padova, Silvia, et al.
Publicado: (2019)

The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment
por: Brighi, Nicole, et al.
Publicado: (2019)

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer
por: Weickhardt, Andrew J., et al.
Publicado: (2022)

Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide
por: Gurioli, Giorgia, et al.
Publicado: (2020)

The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer
por: Schepisi, Giuseppe, et al.
Publicado: (2023)

New Directions and Challenges in Targeted Therapies of Advanced Bladder Cancer: The Role of FGFR Inhibitors
por: Szklener, Katarzyna, et al.
Publicado: (2022)

Targetable Pathways in Advanced Bladder Cancer: FGFR Signaling
por: Xiao, Jin-Fen, et al.
Publicado: (2021)

Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy
por: Schepisi, Giuseppe, et al.
Publicado: (2021)

Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients
por: Farolfi, Alberto, et al.
Publicado: (2023)

Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma
por: Lyou, Yung, et al.
Publicado: (2022)

Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide
por: Conteduca, Vincenza, et al.
Publicado: (2022)

Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy
por: Bergerot, Cristiane Decat, et al.
Publicado: (2019)

Exploring the FGFR3-related oncogenic mechanism in bladder cancer using bioinformatics strategy
por: Cao, Wei, et al.
Publicado: (2017)

Immune-Checkpoint Inhibitors in Advanced Bladder Cancer: Seize the Day
por: Maiorano, Brigida Anna, et al.
Publicado: (2022)

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
por: Facchinetti, Francesco, et al.
Publicado: (2023)

Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden
por: Maia, Manuel Caitano, et al.
Publicado: (2017)

Severe Complications in Testicular Germ Cell Tumors: The Choriocarcinoma Syndrome
por: Rejlekova, Katarina, et al.
Publicado: (2019)

Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis
por: Dizman, Nazli, et al.
Publicado: (2020)

Randomized trial assessing impact of probiotic supplementation on gut microbiome and clinical outcome from targeted therapy in metastatic renal cell carcinoma
por: Dizman, Nazli, et al.
Publicado: (2020)

The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer
por: Komura, Kazumasa, et al.
Publicado: (2023)

Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC targeted therapy
por: Wang, Zechen, et al.
Publicado: (2023)

Oncogenic FGFR3 gene fusions in bladder cancer
por: Williams, Sarah V., et al.
Publicado: (2013)

Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment
por: Gianni, Caterina, et al.
Publicado: (2022)

Cancer Therapy Targeting CD47/SIRPα
por: Dizman, Nazli, et al.
Publicado: (2021)

FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma
por: Tao, Zhanchao, et al.
Publicado: (2022)

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors
por: Javle, Milind, et al.
Publicado: (2023)

Would the combination of everolimus with endocrine-therapy help in FGFR2 positive serous endometrial cancer?
por: Cappelletti, Maria Rosa, et al.
Publicado: (2015)

Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel
por: Gurioli, Giorgia, et al.
Publicado: (2022)

Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors
por: Rizzo, Alessandro
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4b75kk304nd7cpk9ptuso79rcj